TABLE 3.

Correlation of QRDR changes with ciprofloxacin and trovafloxacin activity on the quinolone-sensitive Neisseria meningitidis AN-JA and 44 in vitro-generated mutants with decreased quinolone sensitivity

Strain codeLineageMIC (mg/liter)aDifferencebQRDR alteration(s)
int ciptvaGyrAParC
AN-JAParent0.0160.03+1nilNil
V2F10.1250.06−1Asp95AsnNot tested
V1F10.380.25−0.5Thr91IleNil
V6, V10, V120.380.25−0.5Thr91IleNil
V7V1, F20.380.125−1.5Thr91IleNil
V200.380.5+0.5Thr91IleNil
V14V2, F20.380.25−0.5Thr91Ala, Asp95AsnNil
V220.380.25−0.5Thr91Ile, Asp95AsnNil
V5 and V15V1, F20.50.25−1Thr91IleNil
V170.51+1Thr91IleNil
V16 and V210.750.5−0.5Thr91IleNil
V18V1, F20.750.25−1.5Thr91IleNil
V4, V8, V9, V130.750.5−0.5Thr91IleGlu91Gly
V11 and V190.751+0.5Thr91IleAsp86Asn
V23V2, F20.750.5−0.5Thr91Ile, Asp95AsnNil
V25, V26, V30V1, F332−0.5Thr91Ile, Asp95AsnGlu91Gly
V28 and V3334+0.5Thr91Ile, Asp95AsnAsp86Asn
V39V2, F342−1Thr91Ile, Asp95AsnGlu91Gly
V37V2, F3616+1.5Thr91Ile, Asp95AsnGly85Asp
V3864−0.5Thr91Ile, Asp95AsnGlu91Lys
V41V1, F462−1.5Thr91Ile, Asp95AsnGlu91Gly
V54V2, F464−0.5Thr91Ile, Asp95AsnGlu91Gly
V42 and V43V1, F482−2Thr91Ile, Asp95AsnGlu91Gly
V4884−1Thr91Ile, Asp95AsnGlu91Gly
V47880Thr91Ile, Asp95AsnAsp86Asn
V44 and V45V1, F4124−1.5Thr91Ile, Asp95AsnGlu91Gly
V46124−1.5Thr91Ile, Asp95AsnAsp86Asn
V53V2, F4128−0.5Thr91Ile, Asp95AsnGlu91Lys
V49V1, F4164−2Thr91Ile, Asp95AsnGlu91Gly
V50 and V51V2, F416160Thr91Ile, Asp95AsnGly85Asp
V52168−1Thr91Ile, Asp95AsnGlu91Lys
  • a int cip, intermediate ciprofloxacin MICs, IDS; tva, trovafloxacin MICs, doubling dilution series.

  • b Fold difference in activity between cip and tva.